Top 10 Companies in the Global Poly(D,L-lactide-co- glycolide) (PLGA) Market (2026): Market Leaders Powering Advanced Biomedical Solutions

MARKET INSIGHTS

Global Poly(D,L-lactide-co-glycolide) (PLGA) market size was valued at USD 1.2 billion in 2024. The market is projected to grow from USD 1.3 billion in 2025 to USD 2.4 billion by 2032, exhibiting a CAGR of 9.9% during the forecast period.

Poly(D,L-lactide-co-glycolide) (PLGA) is a biodegradable and biocompatible copolymer synthesized from lactic acid and glycolic acid. It is widely utilized in biomedical applications due to its tunable degradation properties, which allow controlled release of drugs and support tissue regeneration. PLGA’s versatility enables its use in forms such as microspheres, implants, and scaffolds, making it essential for advancing drug delivery systems and medical devices.

The market is experiencing steady growth driven by rising demand for biodegradable materials in pharmaceuticals and medical devices, alongside advancements in regenerative medicine. Furthermore, increasing investments in personalized medicine and the prevalence of chronic diseases are boosting adoption. Key players are innovating to enhance PLGA’s performance; for instance, in 2023, Evonik expanded its RESOMER portfolio with new PLGA grades for sustained drug release. Evonik, Corbion, and Mitsui Chemicals stand out as leading companies with diverse product offerings in this space.

Global Poly(D,L-lactide-co- glycolide) (PLGA) Market – View in Detailed Research Report

Top 10 Companies in the Global PLGA Market

1️⃣ Evonik Industries

Headquarters: Essen, Germany
Key Offering: High‑purity RESOMER PLGA grades for drug delivery, tissue engineering, and implantable devices

Evonik’s RGD platform delivers copolymers with precise lactide‑to‑glycolide ratios, enabling predictable degradation profiles that meet stringent regulatory expectations. The company’s recent expansion of the RESOMER portfolio includes grades tailored for extended release of chemotherapeutics and biologics, positioning Evonik as a primary supplier for advanced therapeutics.

Sustainability & Growth Initiatives:

• Investment in green polymer synthesis to lower carbon footprint
• Partnerships with global pharmaceutical developers to co‑develop next‑generation PLGA formulations
• Expansion of production capacity in Southeast Asia to secure supply chain resilience

2️⃣ DSM

Headquarters: Heerlen, Netherlands
Key Offering: Broad PLGA portfolio for drug delivery and medical devices

DSM has strengthened its position through strategic acquisitions of niche polymer developers, enabling rapid introduction of specialty PLGA blends with enhanced mechanical properties for orthopedic and cardiovascular applications.

Sustainability & Growth Initiatives:

• Investment in bio‑based monomer sourcing to reduce dependency on petrochemicals
• Collaboration with academic institutions for polymer innovation
• Commitment to circular economy principles in polymer production

3️⃣ Mitsui Chemicals

Headquarters: Tokyo, Japan
Key Offering: Advanced copolymer blends for sustained drug release and implantable devices

Focusing on high‑performance formulations, Mitsui Chemicals delivers PLGA grades with controlled crystallinity, extending shelf life and improving load‑bearing capacity for bone graft substitutes.

Sustainability & Growth Initiatives:

• Development of low‑energy polymerization processes
• Partnerships with medical device manufacturers to embed PLGA in next‑generation implants
• R&D into biodegradable composites for load‑bearing applications

4️⃣ Corbion

Headquarters: Rijswijk, Netherlands
Key Offering: Bio‑based PLGA blends for drug delivery and regenerative medicine

Corbion integrates renewable monomers into its PLGA portfolio, targeting markets that demand low environmental impact and compliance with green chemistry standards.

Sustainability & Growth Initiatives:

• Scaling up bio‑based monomer production to meet global demand
• Collaboration with biopharmaceuticals to embed sustainability into product development
• Implementation of life‑cycle assessment tools for product transparency

5️⃣ BMG

Headquarters: Madison, United States
Key Offering: Custom copolymer formulations for medical device manufacturers

BMG’s streamlined supply chain delivers rapid turnaround for tailored PLGA grades, supporting U.S. device makers in meeting regulatory timelines.

Sustainability & Growth Initiatives:

• Joint venture with polymer analytics firm to enhance repeat unit precision
• Focus on high‑performance medical device applications
• Investment in digital manufacturing platforms for rapid prototyping

6️⃣ BioMedTek

Headquarters: Boston, United States
Key Offering: Near‑real‑time PLGA microsphere formulation for drug delivery

BioMedTek’s rapid prototyping facilities reduce lead times for clinical trials, enabling small‑to‑medium pharmaceutical developers to access PLGA microspheres without high upfront tooling costs.

Sustainability & Growth Initiatives:

• Modular copolymer libraries to accelerate product development
• Collaboration with contract research organizations for streamlined regulatory pathways
• Focus on scalable, low‑energy production processes

7️⃣ Shanghai Divine Medical Technology

Headquarters: Shanghai, China
Key Offering: Rapid PLGA microsphere production for local and international markets

Shanghai Divine leverages advanced manufacturing to deliver PLGA microspheres with consistent particle size distribution, supporting oncology and regenerative medicine applications in China and beyond.

Sustainability & Growth Initiatives:

• Investment in high‑purity monomer sourcing to ensure batch consistency
• Partnerships with Chinese pharmaceutical firms for co‑development
• Adoption of digital quality management systems for traceability

8️⃣ Sartorius AG

Headquarters: Göttingen, Germany
Key Offering: PLGA formulation services for biopharmaceuticals

Sartorius provides end‑to‑end PLGA development, from polymer synthesis to scale‑up, supporting biopharma in delivering controlled‑release therapeutics.

Sustainability & Growth Initiatives:

• Integration of process analytical technology for real‑time monitoring
• Collaboration with global pharma to embed sustainability in product design
• Investment in renewable energy for manufacturing facilities

9️⃣ Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: PLGA-based drug delivery systems for oncology

Merck’s PLGA formulations are used in its portfolio of targeted therapeutics, leveraging the polymer’s ability to modulate release kinetics for improved patient outcomes.

Sustainability & Growth Initiatives:

• Development of bio‑based monomer blends to reduce environmental impact
• Partnerships with academic research centers for polymer innovation
• Investment in scalable, energy‑efficient production lines

🔟 Boehringer Ingelheim

Headquarters: Ingelheim am Rhein, Germany
Key Offering: PLGA carriers for biologics and vaccines

Boehringer’s PLGA platforms support the delivery of protein therapeutics and vaccine adjuvants, addressing the need for stable, controlled release in global markets.

Sustainability & Growth Initiatives:

• Implementation of circular economy principles in polymer production
• Collaboration with global health organizations to expand vaccine delivery
• Investment in green chemistry for polymer synthesis

Global Poly(D,L-lactide-co- glycolide) (PLGA) Market – View in Detailed Research Report

Global Poly(D,L-lactide-co- glycolide) (PLGA) Market – View in Detailed Research Report

Outlook

Between 2026 and 2034, the PLGA market is poised to expand as new therapeutic indications emerge and regulatory frameworks mature. The shift toward implantable drug delivery devices, coupled with growing emphasis on personalized medicine, will drive demand for high‑performance PLGA grades with tailored degradation profiles. Market players that invest in scalable, low‑energy production and establish strong partnerships with device manufacturers will capture the largest share of this growth.

Future Trends

• Emergence of patient‑specific PLGA scaffolds enabled by additive manufacturing
• Integration of PLGA carriers into implantable biosensors and minimally invasive delivery systems
• Advancements in bio‑based monomer sourcing to reduce carbon intensity
• Expansion of regulatory pathways for combination products incorporating PLGA
• Growth of digital platforms for real‑time monitoring of PLGA degradation in vivo